• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Accelerate Diagnostics, Inc. (AXDX)

    18.72 0.25(1.35%) Dec 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Accelerate Diagnostics, Inc.
    3950 South Country Club
    Suite 470
    Tucson, AZ 85714
    United States - Map
    Phone: 520-365-3100
    Fax: 520-269-6580
    Website: http://www.acceleratediagnostics.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:47

    Business Summary 

    Accelerate Diagnostics, Inc. focuses on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel system, a rapid diagnostic platform for rapid diagnosis in life-threatening infectious pathogens. It also develops and licenses OptiChem surface coatings for use in microarraying components. Accelerate Diagnostics, Inc. has a research collaboration with U.S. Centers for Disease Control and Prevention to develop tests for the rapid analysis of antibiotic-resistant biothreat agents based on Accelerate's high-speed identification and antibiotic susceptibility testing platform. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is based in Tucson, Arizona.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Accelerate Diagnostics, Inc.

    Corporate Governance 
    Accelerate Diagnostics, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 4; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Lawrence Mehren , 48
    Chief Exec. Officer, Pres and Director
    Mr. Steve Reichling , 36
    Chief Financial Officer, Chief Accounting Officer and Sec.
    Mr. Pete Bantock , 48
    Chief Commercial Officer
    Dr. David W. Grainger Ph.D., 54
    Chairman of Scientific Advisory Board and Consultant
    Dr. Marin H. Kollef M.D., FACP, FCCP, 57
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders